(March 27, 2019, 1:58 PM EDT) -- NEW YORK — The Second Circuit U.S. Court of Appeals on March 26 affirmed that Eliquis lawsuits were properly removed to federal court and that a multidistrict litigation judge properly dismissed the claims as preempted, actions that effectively shut down the MDL in its nascent stage (Catherine Gibbons, et al. v. Bristol-Myers Squibb Company, et al., No. 17-2638, et al., 2nd Cir., 2019 U.S. App. LEXIS 9010)....